Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities.
Rhoanne C McPherson, Stephen M Anderton
https://pubmed.ncbi.nlm.nih.gov/23568718Actively Recruiting
Age: 18Years +
All Genders
Healthy Volunteers
ID06502015
Biomarkers of Neurological Autoimmune Diseases to Support Early Diagnosis and Personalized Treatment
Led by Tongji Hospital · Updated on 2024-11-20
50000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Neurological autoimmune diseases involve the immune system mistakenly attacking the nervous system, affecting the brain, spinal cord, and peripheral nerves. These disorders are diverse, hard to diagnose, and lack effective treatments. This research focuses on eight types of neurological autoimmune diseases, such as Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, idiopathic inflammatory myopathy, multiple sclerosis, autoimmune encephalitis, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. The goal is to find biomarkers that can help with early diagnosis, disease monitoring, and personalized treatment. The study will observe participants with these autoimmune diseases and healthy individuals matched by age and sex. Researchers will collect and analyze samples like blood, feces, bone marrow, and lymph nodes to discover and validate new biomarkers using advanced methods such as proteomics, metabolomics, and sequencing technologies. These biomarkers may provide sensitive, specific, and stable indicators important for prognosis and treatment. Participants will be evaluated over a long period, with the primary outcome being all-cause mortality tracked for 10 years. Researchers will also monitor the occurrence of any autoimmune diseases during this time. Throughout the study, data will be collected without intervention, and participants will undergo assessments to support the discovery of biomarkers that may improve understanding and management of neurological autoimmune diseases.
CONDITIONS
Brief Title
Biomarkers in Autoimmune Disease of Nervous System
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis with neurological autoimmune diseases such as Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, idiopathic inflammatory myopathy, multiple sclerosis, autoimmune encephalitis, or Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
- Healthy individuals matched by age and sex with the patient group
- Adults aged 18 years or older
You will not qualify if you...
- Known history of primary immunodeficiency (innate or acquired)
- Severe central nervous system, lung, or other systemic infections
- Secondary central nervous system demyelinating lesions caused by vasculitis, systemic lupus erythematosus, or Sj�f6gren's syndrome
- Vascular, hereditary metabolic, neoplastic, or toxic diseases
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Initial testing at enrollment with ongoing assessments as needed
Participants undergo diagnostic testing to discover and validate novel biomarkers related to neurological autoimmune diseases using blood, feces, bone marrow, and lymph nodes samples.
1 to 2 visits depending on biomarker assessments
Long-term Monitoring
Duration - Up to 10 years
Participants are monitored over a long-term period to observe outcomes such as all-cause mortality and development of autoimmune diseases.
Periodic visits as determined by study protocol
Trial Site Locations
Total: 1 location
1
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China, 430030
Actively Recruiting
Loading map...
Research Team
L
Luo-qi Zhou, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
A global perspective on the burden of multiple sclerosis.
Egon Stenager
https://pubmed.ncbi.nlm.nih.gov/30679041Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.
Andrew J Solomon, Georgina Arrambide, Wallace J Brownlee...
https://pubmed.ncbi.nlm.nih.gov/37479377